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ABSTRACT: Self-cleaving ribozymes engineered to be activated or inhibited by a small molecule binding to an RNA aptamer
inserted within a ribozyme (aptazymes) have proven to be useful for controlling gene expression in living cells. In mammalian
cells, an aptazyme embedded in the 5′ or 3′ untranslated region of an mRNA functions as a synthetic riboswitch to chemically
regulate gene expression. However, the variety of aptazyme architectures and the ribozyme scaffolds that have been used for
mammalian riboswitches has been limited. In particular, fewer synthetic riboswitches that activate gene expression in response
to a small molecule (ON-switches) in mammalian cells have been reported compared to OFF-switches. In this work, we
developed mammalian riboswitches that function as guanine-activated ON-switches based on a novel aptazyme architecture in
which an aptamer and a ribozyme are fused in tandem. The riboswitch performance was optimized by fine-tuning the stability of
a critical stem that controls the ribozyme structure and function, yielding switches with ON/OFF ratios greater than 6.0. Our
new aptazyme architecture expands the RNA device toolbox for controlling gene expression in mammalian cells.
KEYWORDS: RNA engineering, twister ribozyme, aptamer, aptazyme, riboswitch
Synthetic riboswitches enable chemical regulation of geneexpression without engineered proteins. An aptamer, or a
short segment of RNA that specifically binds its target
molecule, acts as a chemical sensor, and various mechanisms
are used to couple aptamer-target binding with gene expression
at the RNA level.1−4 In mammalian cells, insertion of one or
more allosterically controlled ribozymes, or aptazymes, in the
5′ or 3′ untranslated region (UTR) of the mRNA of the gene
to be regulated is a well-established strategy to regulate gene
expression by a small molecule.5 The aptazyme consists of a
self-cleaving ribozyme and an aptamer designed so that self-
cleavage is either activated or inhibited by a small molecule
that binds to the aptamer. Ribozyme cleavage within the UTR
of an mRNA results in diminished gene expression (OFF),
whereas ribozyme inhibition upregulates the encoded protein
expression (ON).
These self-cleaving aptazymes represent compact, cis-acting,
and portable RNA devices to control gene expression in
mammalian cells. Recent applications of aptazyme-based
riboswitches in mammalian cells and animals include chemical
regulation of T-cell proliferation,6 and controlling viral
replication and viral gene expression.7−12 However, the variety
of aptazymes that have been experimentally demonstrated in
mammalian cells remains limited. Aptazymes are typically
designed by inserting an aptamer within a stem loop of a
ribozyme, and by optimizing the “communication module”
that bridges the two RNA elements via extensive screening or
design-build-test cycles.6,12−16 To date, only the hammerhead
and the hepatitis delta virus (HDV) ribozymes have been used
to engineer riboswitches in mammalian cells. Interestingly,
OFF-switches (downregulation of gene expression in response
to a small molecule) are more common,12−15,17 whereas only a
few aptazyme-based ON-switches have been reported in
mammalian cells.6,16,18,19
We recently described a novel architecture for small
molecule-inhibited aptazymes.20 Instead of inserting an
aptamer within a stem loop of a ribozyme, an aptamer and a
ribozyme were fused in tandem. Furthermore, an antiribozyme
(anti-Rz) sequence was inserted upstream of the aptamer
which is partially complementary to the ribozyme sequence
(Figure 1). In this design, the aptazyme can adopt either the
ribozyme (Rz) or the aptamer (Apt) structure. The two
structures are exclusive, and only the Rz structure results in
self-cleavage (gene expression OFF). The base stem of the
ribozyme Prz is an essential structural element of the ribozyme.
Similarly, formation of Papt, the base stem of the aptamer which
includes the 5′ side of Prz, is also critical for ligand binding
(Figure 1). It is expected that if Papt is too stable, the aptazyme
assumes the Apt structure; therefore, gene expression is ON. If
Papt is too unstable, and therefore Prz is too stable, the
aptazyme forms the Rz structure resulting in low gene
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Figure 1. Schematic representation of the mammalian riboswitch based on the aptamer-ribozyme fusion architecture. The aptazyme preferentially
forms the Rz structure which retains the active ribozyme fold in the absence of the aptamer ligand, resulting in mRNA cleavage. Aptamer-ligand
binding disrupts the ribozyme fold (Apt) to prevent mRNA cleavage, and therefore allows protein translation.
Figure 2. Optimization of P3apt size in the aptazyme architecture. (A) Predicted secondary structures of GuaTw (no upstream complementary
bases) and 14c (14-base upstream complementary bases) aptazyme candidates. Red arrowhead indicates the cleavage site. (B) Normalized EGFP
expression levels of the riboswitch variants in the absence and presence (250 μM) of guanine. EGFP: empty vector with no aptazyme. The data are
averages of 3 replicate samples and the error bars represent SD. (C) Gibbs free energies (ΔG) of Apt and Rz structures calculated by Mfold. The
structures were constrained to either Apt- or Rz-like folds by entering the constraint information provided in Table S1.
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expression (OFF). However, an optimal Papt stability may shift
the equilibrium of the aptazyme structures toward the Apt state
in the presence of the aptamer ligand by selectively stabilizing
the Apt structure, resulting in upregulation of gene expression
(ON-switch). This aptazyme architecture was demonstrated
using a guanine aptamer21 and a pistol ribozyme22 in vitro.20
Unfortunately, however, the pistol ribozyme was not functional
in mammalian cells; therefore, the tandem aptamer-ribozyme
architecture was not implemented as a riboswitch.
In this work, we report successful design of guanine-
activated riboswitches in mammalian cells based on this
aptazyme architecture. Specifically, we used a guanine aptamer
and a twister ribozyme22 (first riboswitch application in
mammalian cells), and systematically optimized the aptazyme
design to yield mammalian ON-switches with ON/OFF ratios
exceeding 6.0. This aptazyme design strategy expands the
currently limited toolbox of RNA devices to control gene
expression in mammalian cells.
■ RESULTS AND DISCUSSION
Twister ribozymes have been identified in many species of
bacteria and eukaryotes,23 and some variants have been shown
to function efficiently in heterologous hosts. Felletti et al. used
a twister ribozyme identified in the environmental DNAs to
design synthetic riboswitches in Escherichia coli and Saccha-
romyces cerevisiae.24 More recently, Litke and Jaffrey used a
twister ribozyme from Nematostella vectensis to generate
circular RNAs in mammalian cells.25 Consequently, we also
used the twister ribozyme from N. vectensis (simply referred to
as Tw in this article) to design mammalian riboswitches.
We first confirmed the ribozyme activity in HEK293 cells by
inserting Tw in the 3′ UTR of EGFP mRNA. The plasmid
Figure 3. Optimization of P3apt stability in the aptazyme architecture by introducing mismatches. (A) Representative Apt and Rz structures
illustrated for the 7c variant. (B) Normalized EGFP expression levels of the riboswitch variants in the absence and presence (250 μM) of guanine.
EGFP: empty vector with no aptazyme. (C) Dose-dependent EGFP expression of 7c4x. The data are fitted to the Hill equation which is shown as
the solid curve. (D) Fluorescence micrographs of the cells shown in (C). (B−C): The data are averages of 3 replicate samples, and the error bars
represent SD.
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encoding the ribozyme-embedded EGFP and another plasmid
constitutively expressing mCherry (used to normalize for
transfection efficiency) were cotransfected into HEK293 cells,
and cellular fluorescence was measured after 48 h. Expression
of the Tw-embedded EGFP was suppressed by 96% compared
to the control plasmid without ribozyme (Figure 2B),
indicating fast self-cleavage of Tw in mammalian cells. Next,
we inserted the core guanine aptamer sequence (Gua) directly
upstream of Tw to produce GuaTw (Figure 2A). Fusion of
Gua does not significantly interfere with the ribozyme activity
of Tw as observed in the low EGFP fluorescence of the
GuaTw-containing construct (Figure 2B).
Figure 4. Effect of the mismatch position in the base stem of the guanine aptamer on Kd. (A) Stem variants of the aptamer studied by ITC. ITC
results of the variants (B) 6c, (C) 6c1x, (D) 6c3x, and (E) 6c5x. Additional thermodynamic parameters obtained are provided in Table S2. The
observations of binding stoichiometry (N) values lower than 1.0 have been reported for the guanine and other aptamers, probably due to the
formation of nonfunctional complexes or misfolding.27,28
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We then extended the base stem of the guanine aptamer
(P3apt) which directly competes with the P3 stem of the
ribozyme (P3rz) (Figure 2A). On the basis of our previous
work,20 we envisioned that stabilization of P3apt would result in
increased EGFP fluorescence due to the disruption of the
competing P3rz. As shown in Figure 2B, increasing the number
of bases in P3apt that are complementary to Tw from 2 (2c) to
14 (14c) resulted in a gradual increase in EGFP fluorescence
up to 12c where the EGFP level reaches a plateau. The same
trend was observed in the presence of 250 μM guanine;
however, EGFP expression mostly leveled off at 5c (Figure
2B). Consequently, the constructs 4c-8c functioned as
guanine-activated riboswitches with ON/OFF ratios of
approximately 3 or more.
Inactivation of Tw23 in 14c (i14c) reduced the EGFP
expression level relative to the empty vector by ∼27% (Figure
S1), suggesting that the insertion of the sequence elements
(ribozyme and aptamer) in the 3′UTR negatively affects the
basal expression level in the absence of ribozyme cleavage. The
EGFP expression level of 14c was ∼73% of that of i14c
indicating that the P3apt in 14c mostly, although not
completely, inhibits the ribozyme activity (Figure S1).
The results are consistent with our mechanistic hypothesis.
When P3apt is weak (2c-4c), the aptazyme mostly adopts the
Rz structure (Figure 1, left); therefore, the ribozyme is active
and EGFP is downregulated. When P3apt is strong (12c and
14c), the aptazyme is biased toward the Apt structure (Figure
1, right), resulting in high EGFP expression. Intermediate
stability of P3apt, however, makes the relative stabilities of Rz
and Apt structures dependent on the presence of guanine
bound to the aptamer. Specifically, aptamer-guanine binding
stabilizes the Apt structure relative to the Rz structure,
therefore activating EGFP expression. The predicted free
energy values of folding (ΔG)26 of the Apt and Rz forms for
the aptazymes indicate that while the Rz stability is unaffected
by the number of upstream complementary bases (anti-Rz),
the Apt structure stabilizes as the number of complementary
bases increases (Figure 2C). We observed a sigmoidal
relationship between EGFP expression and the energy
difference of Rz and Apt structures (ΔGrz − ΔGapt) (Figure
S2). Consistent with the assumption that guanine binding
shifts the equilibrium toward Apt, the increase in EGFP
expression is observed at lower ΔGrz − ΔGapt in the presence
of guanine, resulting in a small window (ΔGrz − ΔGapt = ∼5−
10 kcal/mol) in which the switching is observed. Con-
sequently, adjusting the relative stability of P3rz and P3apt
appears to be a viable strategy for optimizing the riboswitch
performance.
Simply by changing the number of complementary bases to
Tw in P3apt, 5c, 6c, and 7c show respectable ON/OFF ratio of
3.0 to 5.3 (Figure 2B). We sought to further improve the
riboswitch performance by lowering the OFF level in the
absence of guanine. One way to achieve this is to destabilize
P3apt relative to P3rz by introducing a mismatch in P3apt while
keeping P3rz constant (Figure 3). Such a mutation would be
expected to shift the equilibrium in favor of the Rz structure,
and therefore to lower the EGFP expression level in the
absence of guanine. By systematically introducing a mismatch
within the P3apt stems of 5c, 6c, and 7c, we indeed observed
reduction of the OFF levels in all variants (Figure 3B). Lower
OFF levels of several variants contributed to the improved
ON/OFF ratios with 4 variants displaying ON/OFF ratios
greater than 6.0. The dose-dependent response of the variant
7c4x which showed an ON/OFF ratio of 6.7 was analyzed
(Figure 3C,D). The riboswitch showed an EC50 of 63 μM
which is comparable to that of the OFF-switch GuaM8HDVRz
previously reported.15
A notable observation in Figure 3B is that the OFF level in
the absence of guanine is largely unaffected by the position of
the mismatch within P3apt, but the ON level in the presence of
guanine generally increases as the mismatch is located further
away from the aptamer. The stability of the Apt structure in the
absence of guanine, therefore, the OFF level, is expected to be
mostly unaffected by the position of a mismatch within P3apt.
However, the stability of the Apt structure in the presence of
guanine is affected by proximity of the mismatch within P3apt
to the aptamer. A mismatch close to the guanine aptamer is
more detrimental to guanine binding compared to a mismatch
further away. Consequently, the riboswitch ON levels in the
presence of guanine are lower when the mismatches are
located closer to the aptamer (Figure 3B). This hypothesis was
confirmed by measuring the dissociation constants (Kd) of
guanine aptamers with and without a mismatch within the base
stem (Figure 4). A mismatch proximal to the aptamer (6c1x)
increased the Kd by 25-fold over the aptamer without a
mismatch (6c). The Kd was 6.5-fold higher for 6c3x and 2.6-
fold higher for 6c5x, consistent with the observations.
These observations are somewhat reminiscent of those by
Zhong et al.,12 who developed a scoring function to optimize
the stability of the stem that connects an aptamer and a
hammerhead ribozyme to optimize ligand-activated aptazymes
that function as OFF-switches in mammalian cells. One of the
key elements of their scoring function was to weigh the
contributions of the base pairs closer to the ribozyme more
than those further away. While the ribozyme architectures and
the mode of the switches are different, the results underscore
the importance of local stability within aptamer-ribozyme
communication modules for the riboswitch performance.
Our results suggest that not only the relative stability of Apt
and Rz structures, but also the subtle local stability within the
stem structures influences the switch performance. While we
focused on P3apt for optimization, fine-tuning the stability of
P3rz may also prove to be a productive strategy. It should be
noted, however, that while destabilization of P3rz would likely
increase the ON level, it may also increase the OFF level by
destabilizing the ribozyme structure. Again, the local stability
within P3rz may affect the overall switch characteristics.
Furthermore, mutations other than a mismatch, for example,
introduction of a G-U wobble pair or a bulge (insertion), may
also be worth testing. Consequently, more systematic and high-
throughput screening of a larger set of mutants19,29 guided by
the structure−function relationship insights gained from this
work may lead to further improvement of the riboswitch
performance.
Although aptazyme-based riboswitches are the most
frequently reported synthetic riboswitches in mammalian
cells, only a handful of ON-switches have been reported.
Furthermore, all of the existing ON-switches are based on
inserting an aptamer in one of the stem-loops in a
hammerhead ribozyme.6,16−18 For example, the Suess group
engineered an ON-switch by inserting the tetracycline aptamer
in the P1 stem of a hammerhead ribozyme.18 In that design,
the nucleotides involved in the loop−loop interaction crucial
for ribozyme activity were sequestered upon ligand binding.
One of the variants K19 yielded a good ON/OFF ratio (8.7).
Other existing aptazyme-based ON-switches have displayed
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more modest ON/OFF ratios. The Hartig group recently
demonstrated the modularity of the K19 riboswitch by
changing the tetracycline aptamer to guanine aptamer resulting
in a lower ON/OFF ratio of 4.0.16 Similarly, the Smolke group
has reported a theophylline activated riboswitch with the
aptamer inserted within the P2 stem of a hammerhead
ribozyme that shows an ON/OFF ratio of 3.1 in transiently
transfected BHK cells.7
Even including the reported OFF-switches, the variety of
aptamers, ribozymes, and aptazyme architectures used in
mammalian riboswitches remains rather limited. Only two
ribozyme classes (hammerhead and HDV ribozymes) have
been used, and in all cases, an aptamer was inserted in a stem
or a loop region within the ribozyme scaffold. To our
knowledge, our work represents the first application of a
twister ribozyme to regulate gene expression in mammalian
cells. Additionally, the tandem aptamer-ribozyme architecture
was demonstrated to function in living cells for the first time,
yielding mammalian riboswitches with an ON/OFF ratio up to
6.7 through semirational and systematic fine-tuning of the Papt
stability. The new architecture expands the available RNA
elements and design strategies for mammalian riboswitches.
Future goals include extension of the riboswitch architecture
to other aptamers and ribozyme scaffolds, and optimization of
the design strategy by identifying additional key sequence
elements that affect riboswitch performance.
■ METHODS
Riboswitch Plasmid Preparation. All plasmids were
constructed by standard recombinant DNA techniques and
sequence verified by Sanger sequencing. The EGFP-aptazyme
constructs were derived from pEGFP-N1-BspEI (Figure S3,
Supporting Information, Appendix). The inserted riboswitch
sequences are listed in Table S3. Plasmids used for transfection
were purified using Zyppy Plasmid Miniprep kit (Zymo
Research).
HEK293 Cell Culture and Transfection. HEK293 cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated FBS
(Gibco) containing 2 mM L-glutamine and 100 units/mL of
penicillin-streptomycin (DMEM-FBS). Cells were kept in a
37°C incubator with 5% CO2 and passaged regularly upon
reaching 90% confluency. Approximately 20 h prior to
transfection, the cells were trypsinized, diluted to ∼2.7 × 105
cells/mL and 100 μL/well were seeded onto a 96-well plate.
Cells in each well were cotransfected with 100 ng of the EGFP-
aptazyme plasmid and 20 ng of pCMV-mCherry (transfection
control) using 0.3 μL of TransIT-293 Transfection Reagent
(Mirus) according to the manufacturer’s instructions. Five
hours after transfection, the medium in each well was replaced
with fresh medium with (250 μM) or without guanine.
Guanine was dissolved at 25 mM in 0.2 M NaOH which was
diluted by 100-fold in DMEM-FBS. The same volume of 0.2 M
NaOH solution was diluted in DMEM-FBS for the medium
without guanine. Forty-eight hours after transfection, the
medium in each well was replaced with 100 μL of phosphate
buffered saline (PBS), and fluorescence intensity was measured
by Infinite M1000 PRO microplate reader (Tecan).
Fluorescence intensity was measured at 484 nm excitation/
510 nm emission/5 nm bandwidth for EGFP, and at 587 nm
excitation/610 nm emission/10 nm bandwidth for mCherry.
Background fluorescence measured using untransfected cells
was subtracted from the EGFP and mCherry fluorescence
values. Then, EGFP fluorescence was normalized by mCherry
fluorescence to account for variations in transfection efficiency
and cell counts. All reported values are averages of three
replicate wells.
RNA Structure Prediction and Free Energy Calcu-
lation. For the free energy calculations (Figure 2C), aptazyme
sequences were submitted to the Mfold Web Server’s “RNA
Folding Form”.26 The structure was constrained to either the
Apt or Rz structure by forcing appropriate base pairs. The
“constraint information” parameters used are listed in Table
S1.
ITC Measurements. Guanine (Sigma-Aldrich) was dis-
solved in 1 N HCl/ethyl acetate solution and incubated at
room temperature for few minutes. The solvent was removed
by evaporation and the pellet was suspended in n-hexane. The
solvent was removed again by evaporation to obtain guanine
hydrochloride. Saturated solution of guanine hydrochloride
was prepared in water and filtered through a 0.2 μm syringe
filter (Merck-Millipore). The concentration was determined by
absorbance using the reported molar extinction coefficient
(ε248 = 11 400 cm
−1 M−1).30 For titration experiments, 70.4
μM guanine solution was prepared in ITC buffer (10 mM
HEPES-KOH, pH 7.5, 140 mM KCl, 10 mM NaCl, 1 mM
MgCl2).
Template DNAs for in vitro transcription were prepared by
primer extension using Q5 High-Fidelity DNA Polymerase
(NEB). Sequences of the oligo DNAs used are shown in Table
S4. The resulting products were size-purified from agarose gel
using a DNA purification kit (Zymoclean Gel DNA Recovery
kit, Zymo Research). RNA aptamers were prepared using
HiScribe T7 High Yield RNA Synthesis Kit (New England
Biolabs) according to the manufacturer’s instructions. The
transcription products (100 μL) were treated with 2 U
TURBO DNase (Thermo Fisher Scientific) at 37 °C for 1 h.
The RNAs were precipitated with ammonium acetate and
ethanol, and then dissolved in water. The solutions were
further extracted with phenol-chloroform and ethanol
precipitated. The RNAs were separated by denaturing
polyacrylamide gel and extracted from the gel with TE buffer
(10 mM Tris-HCl, pH 7.0, 0.1 mM EDTA-Na). The eluents
were filtered through a 0.45 μm syringe filter. The gel-purified
RNA solutions were concentrated, and the buffer was
exchanged to water using an ultrafiltration device (Amicon
Ultra 0.5 mL filter, 3 kDa cutoff, Merck-Millipore). RNA
concentrations were determined by absorbance (A260)
according to OligoCalc.31 For the titration experiments, 7.5
μM RNA solutions were prepared in the ITC buffer. RNAs
were denatured at 65 °C for 3 min and then incubated at room
temperature before measurement.
ITC experiments were performed as described previously
with some modifications.27 The titrations were performed at
37 °C using MicroCal PEAQ-ITC (Malvern). Injection
parameters were as follows: initial 300 s delay, single 0.4 μL
injection, and 24 serial injections of 1.5 μL at intervals of 120 s.
Stirring speed and reference power were set to 700 rpm and
4.5 μcal s−1, respectively. Raw data were analyzed with
MicroCal PEAQ-ITC analysis software ver. 1.0.0.1259
(Malvern) depending on one-site binding model. Background
signals (guanine hydrochloride was titrated against the buffer)
were subtracted from the data. Measurements were repeated
twice to ensure reproducibility.
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